» Articles » PMID: 30796005

Bacterial Viability in Faecal Transplants: Which Bacteria Survive?

Overview
Journal EBioMedicine
Date 2019 Feb 24
PMID 30796005
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The therapeutic potential of faecal microbiota transplantation (FMT) is under investigation for a range of inflammatory conditions. While mechanisms of benefit are poorly understood, most models rely on the viability of transplanted microbes. We hypothesised that protocols commonly used in the preparation of faecal transplants will substantially reduce the number, diversity and functional potential of viable microbes.

Methods: Stools from eight screened donors were processed under strict anaerobic conditions, in ambient air, and freeze-thawed. Propidium monoazide (PMA) sample treatment was combined with quantitative PCR, 16S rRNA gene amplicon sequencing and short-chain fatty acid (SCFA) analysis to define the viable microbiota composition and functional potential.

Findings: Approximately 50% of bacterial content of stool processed immediately under strict anaerobic conditions was non-viable. Homogenisation in ambient air or freeze-thaw reduced viability to 19% and 23% respectively. Processing of samples in ambient air resulted in up to 12-fold reductions in the abundance of important commensal taxa, including the highly butyrogenic species Faecalibacterium prausnitzii, Subdoligranulum variable, and Eubacterium hallii. The adverse impact of atmospheric oxygen exposure on the capacity of the transplanted microbiota to support SCFA biosynthesis was demonstrated by significantly reduced butyrate and acetate production by faecal slurries processed in ambient air. In contrast, while reducing overall levels of viable bacteria, freeze-thaw did not significantly alter viable microbiota composition.

Interpretation: The practice of preparing material for faecal transplantation in ambient air profoundly affects viable microbial content, disproportionately reducing the abundance of anaerobic commensals and the capacity for biosynthesis of important anti-inflammatory metabolites. FUND: This work was supported by the South Australian Health and Medical Research Institute. LP is supported by a scholarship from the Flinders Foundation. GR is supported by a Matthew Flinders Research Fellowship.

Citing Articles

Microbiota transplant therapy in inflammatory bowel disease: advances and mechanistic insights.

Moutsoglou D, Ramakrishnan P, Vaughn B Gut Microbes. 2025; 17(1):2477255.

PMID: 40062406 PMC: 11901402. DOI: 10.1080/19490976.2025.2477255.


In vitro validation concept for lyophilized fecal microbiota products with a focus on bacterial viability.

Sedeek S, Farowski F, Youssafi S, Tsakmaklis A, Brodesser S, El-Attar M World J Microbiol Biotechnol. 2025; 41(3):83.

PMID: 40011318 PMC: 11865215. DOI: 10.1007/s11274-025-04291-0.


Changes in bacterial viability after preparation and storage of fecal microbiota transplantation solution using equine feces.

Arantes J, Di Pietro R, Ratte M, Arroyo L, Leclere M, Costa M PeerJ. 2025; 13:e18860.

PMID: 39989751 PMC: 11847485. DOI: 10.7717/peerj.18860.


Validation methods for encapsulated faecal microbiota transplantation: a scoping review.

Ragard N, Baumwall S, Ellegaard Paaske S, Mejlby Hansen M, Hoyer K, Mikkelsen S Therap Adv Gastroenterol. 2025; 18:17562848251314820.

PMID: 39926318 PMC: 11806493. DOI: 10.1177/17562848251314820.


Prolonged storage reduces viability of and core intestinal bacteria in fecal microbiota transplantation preparations for dogs.

Correa Lopes B, Turck J, Tolbert M, Giaretta P, Suchodolski J, Pilla R Front Microbiol. 2025; 15():1502452.

PMID: 39839105 PMC: 11747423. DOI: 10.3389/fmicb.2024.1502452.


References
1.
Nocker A, Sossa-Fernandez P, Burr M, Camper A . Use of propidium monoazide for live/dead distinction in microbial ecology. Appl Environ Microbiol. 2007; 73(16):5111-7. PMC: 1951001. DOI: 10.1128/AEM.02987-06. View

2.
Frank D, St Amand A, Feldman R, Boedeker E, Harpaz N, Pace N . Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007; 104(34):13780-5. PMC: 1959459. DOI: 10.1073/pnas.0706625104. View

3.
Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran L, Gratadoux J . Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008; 105(43):16731-6. PMC: 2575488. DOI: 10.1073/pnas.0804812105. View

4.
Louis P, Young P, Holtrop G, Flint H . Diversity of human colonic butyrate-producing bacteria revealed by analysis of the butyryl-CoA:acetate CoA-transferase gene. Environ Microbiol. 2009; 12(2):304-14. DOI: 10.1111/j.1462-2920.2009.02066.x. View

5.
Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X . Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 2011; 6(2):320-9. PMC: 3260502. DOI: 10.1038/ismej.2011.109. View